Indrayani Biotech Limited
Bombay Stock ExchangeTotal Valuation
Indrayani Biotech Limited carries a market capitalization of 386.60M, placing it among publicly traded companies globally. Its enterprise value stands at 540.01M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 386.60M |
| Enterprise Value | 540.01M |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | 0.36 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Indrayani Biotech Limited trades at an EV/EBITDA multiple of 39.89 and an EV/FCF ratio of 4.05. The EV/Sales ratio of 0.36 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 39.89 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.36 |
| EV / EBITDA | 39.89 |
| EV / EBIT | 39.89 |
| EV / FCF | 4.05 |
Financial Position
Indrayani Biotech Limited maintains a current ratio of 4.38, meaning it holds 4.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 278.02, indicating elevated leverage, while an interest coverage ratio of 0.11 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.38 |
| Quick Ratio | 0.36 |
| Debt / Equity | 278.02 |
| Debt / EBITDA | N/A |
| Interest Coverage | 0.11 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | N/A |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 12.36 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Indrayani Biotech Limited has paid 4.34M in income taxes, reflecting an effective tax rate of 57.94.
| Income Tax | 4.34M |
| Effective Tax Rate | 57.94 |
Stock Price Statistics
Indrayani Biotech Limited's stock has declined approximately -44.47351% over the past 52 weeks. The 50-day moving average sits at 10.76, while the 200-day moving average is 11.20.
| Beta (5Y) | N/A |
| 52-Week Price Change | -44.47351% |
| 50-Day Moving Average | 10.76 |
| 200-Day Moving Average | 11.20 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Indrayani Biotech Limited generated 1.51B in revenue and converted that into -62.65M in net income, yielding earnings per share of -1.54. EBITDA reached 13.54M, while operating income came in at 13.54M.
| Revenue | 1.51B |
| Gross Profit | 416.55M |
| Operating Income | 13.54M |
| Pretax Income | -69.08M |
| Net Income | -62.65M |
| EBITDA | 13.54M |
| EBIT | 13.54M |
| Earnings Per Share (EPS) | -1.54 |
Margins
Indrayani Biotech Limited operates with a gross margin of 27.65, reflecting its pricing power and cost economics. The operating margin of 0.90 and net profit margin of -4.16 provide insight into operational efficiency.
| Gross Margin | 27.65 |
| Operating Margin | 0.90 |
| Pretax Margin | -4.59 |
| Profit Margin | -4.16 |
| EBITDA Margin | 0.90 |
Stock Splits
Indrayani Biotech Limited's most recent stock split took place on September 24, 2015 with a 25:3 split ratio.
| Last Split Date | 9/24/2015 |
| Split Ratio | 25:3 |
Scores
Indrayani Biotech Limited posts an Altman Z-Score of 2.26, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.26 |